INT65033

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1996
Last Reported 2011
Negated 0
Speculated 0
Reported most in Abstract
Documents 21
Total Number 21
Disease Relevance 12.36
Pain Relevance 2.94

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Fgf2) extracellular space (Fgf2) extracellular region (Fgf2)
nucleus (Fgf2) embryo development (Fgf2) cytoplasm (Fgf2)
Anatomy Link Frequency
endothelial cell 3
fibroblast 2
Plasma 1
muscle 1
pituitary 1
Fgf2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
metalloproteinase 2 100.00 Very High Very High Very High
Spinal cord 5 99.58 Very High Very High Very High
Pain 6 99.36 Very High Very High Very High
Brush evoked pain 1 98.74 Very High Very High Very High
rheumatoid arthritis 39 97.92 Very High Very High Very High
cINOD 8 97.20 Very High Very High Very High
Substantia nigra 4 92.08 High High
chemokine 2 90.48 High High
cva 6 90.04 High High
Arthritis 116 88.00 High High
Disease Link Frequency Relevance Heat
Pituitary Cancer 2 99.60 Very High Very High Very High
Injury 46 99.52 Very High Very High Very High
Neuropathic Pain 10 99.48 Very High Very High Very High
Pain 4 99.36 Very High Very High Very High
Coronary Artery Disease 8 99.28 Very High Very High Very High
Ulcers 60 99.22 Very High Very High Very High
Pressure And Volume Under Development 14 98.72 Very High Very High Very High
Diabetes Mellitus 68 98.64 Very High Very High Very High
Renal Cancer 3 98.54 Very High Very High Very High
Cancer 30 97.98 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These results suggest that endogenous astroglial FGF-2 contributes to maintaining NP tactile allodynia associated with reactivity of spinal cord astrocytes and that inhibition of spinal FGF-2 ameliorates NP pain signs.
Negative_regulation (inhibition) of FGF-2 in astrocytes associated with pain, brush evoked pain, neuropathic pain and spinal cord
1) Confidence 0.59 Published 2005 Journal J. Mol. Neurosci. Section Abstract Doc Link 16280602 Disease Relevance 0.98 Pain Relevance 0.86
By 24 h, 3 months and 6 months after PTCA, bFGF levels had decreased significantly in the PTCA group (3.2+/-0.6, 1.7+/-0.3 and 2.7+/-0.6 pg/ml, respectively, P<0.05).
Negative_regulation (decreased) of bFGF
2) Confidence 0.58 Published 2002 Journal Int. J. Cardiol. Section Abstract Doc Link 12127372 Disease Relevance 0.32 Pain Relevance 0.14
Following PTCA, bFGF levels decreased significantly and remained stable for 6 months after the procedure.
Negative_regulation (decreased) of bFGF
3) Confidence 0.58 Published 2002 Journal Int. J. Cardiol. Section Abstract Doc Link 12127372 Disease Relevance 0.32 Pain Relevance 0.16
Axotomy also elevated the number of GFAP astrocytes (143% after crush; 277% after transection) and nuclear FGF-2 (57% after transection) in astrocytes (confirmed by two-color immunoperoxidase) in the ipsilateral facial nucleus.
Negative_regulation (number) of nuclear FGF-2 in nucleus
4) Confidence 0.43 Published 2010 Journal J Brachial Plex Peripher Nerve Inj Section Abstract Doc Link PMC2995486 Disease Relevance 0.27 Pain Relevance 0
Recombinant VS was shown to inhibit basic fibroblast growth factor (bFGF) and VEGF-induced endothelial cell proliferation in vitro [17].
Negative_regulation (inhibit) of bFGF in endothelial cell
5) Confidence 0.43 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2862241 Disease Relevance 0.93 Pain Relevance 0.05
This study was aimed to compare the effects of selective Cox-2 inhibitor (NS398) versus non-selective Cox inhibitor (indomethacin) on basal and basic fibroblast growth factor (bFGF) - stimulated gastric wound re-epithelialization.
Negative_regulation (inhibitor) of bFGF in fibroblast associated with injury
6) Confidence 0.39 Published 2002 Journal Life Sci. Section Abstract Doc Link 12138016 Disease Relevance 0.68 Pain Relevance 0.07
This study was aimed to compare the effects of selective Cox-2 inhibitor (NS398) versus non-selective Cox inhibitor (indomethacin) on basal and basic fibroblast growth factor (bFGF) - stimulated gastric wound re-epithelialization.
Negative_regulation (inhibitor) of basic fibroblast growth factor in fibroblast associated with injury
7) Confidence 0.39 Published 2002 Journal Life Sci. Section Abstract Doc Link 12138016 Disease Relevance 0.68 Pain Relevance 0.07
These findings indicate that specific Cox-2 inhibitor (NS398) does not interfere with the basal re-epithelialization but significantly inhibits the bFGF - stimulated re-epithelialization, whereas indomethacin interferes with both the basal as well as the bFGF-stimulated wound re-epithelialization.
Negative_regulation (inhibits) of bFGF associated with injury
8) Confidence 0.39 Published 2002 Journal Life Sci. Section Abstract Doc Link 12138016 Disease Relevance 0.52 Pain Relevance 0.07
Both indomethacin and NS398 inhibited bFGF stimulated wound re-epithelialization, with indomethacin having a greater inhibitory effect.
Negative_regulation (inhibited) of bFGF associated with injury
9) Confidence 0.39 Published 2002 Journal Life Sci. Section Abstract Doc Link 12138016 Disease Relevance 0.70 Pain Relevance 0.07
Our data agree with a previous report of upregulated Fgf2 protein levels after 3 months of diabetes in the Sprague Dawley rat [54].
Negative_regulation (report) of Fgf2 associated with diabetes mellitus
10) Confidence 0.35 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3020973 Disease Relevance 0.66 Pain Relevance 0.07
Recombinant VS was shown to inhibit basic fibroblast growth factor (bFGF) and VEGF-induced endothelial cell proliferation in vitro [17].
Negative_regulation (inhibit) of basic fibroblast growth factor in endothelial cell
11) Confidence 0.32 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2862241 Disease Relevance 0.93 Pain Relevance 0.05
Recombinant VS was shown to inhibit bFGF- and VEGF-induced endothelial cell proliferation in vitro [17].
Negative_regulation (inhibit) of bFGF in endothelial cell
12) Confidence 0.32 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2862241 Disease Relevance 0.56 Pain Relevance 0
and bFGF were decreased by 63%, 77% and 63%, respectively, in rats treated with 30 mg/kg/day of pioglitazone (Table 4).
Negative_regulation (decreased) of bFGF
13) Confidence 0.29 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2374462 Disease Relevance 1.00 Pain Relevance 0.24
Local action: Plantar subcutaneous injection of bFGF at above 0.005 mg/site induced edema by itself on and after the next day, and also reinforced carrageenin-induced edema from 1 day after injection.
Negative_regulation (injection) of bFGF associated with pressure and volume under development
14) Confidence 0.28 Published 1996 Journal Arzneimittelforschung Section Abstract Doc Link 8842346 Disease Relevance 0.35 Pain Relevance 0.04
By contrast, NSAIDs, cyclooxygenase-2 (COX-2) inhibitors, and alendronate have been shown to delay the healing of ulcers, and impair angiogenesis and the down regulation of growth factors such as bFGF and VEGF (17-19).
Negative_regulation (regulation) of bFGF associated with ulcers and cinod
15) Confidence 0.22 Published 2010 Journal Journal of Korean Medical Science Section Body Doc Link PMC2877244 Disease Relevance 0.83 Pain Relevance 0.10
In a phase II clinical trial for advanced renal cell carcinoma, patients rendered copper deficient with TM therapy had a significantly decreased serum content of proangiogenic mediators, VEGF, FGF-2, IL-6, and IL-8 [29].
Negative_regulation (decreased) of FGF-2 associated with renal cancer
16) Confidence 0.19 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1297562 Disease Relevance 0.93 Pain Relevance 0.33
Treatments (Dll4 and Ang2, 500 ng/ml; FGF2, 20 ng/ml; JAK inhibitor, 200 nM) were every 2 days.


Negative_regulation (inhibitor) of FGF2
17) Confidence 0.18 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2829079 Disease Relevance 0 Pain Relevance 0.14
Immunohistochemical analysis was used to define the different hormone types of the tumors and the expression of various immunologic targets, including the pituitary tumor transforming gene, basic fibroblast growth factor-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and proliferating cell nuclear antigen.
Negative_regulation (inhibitor) of basic fibroblast growth factor-2 in pituitary associated with cancer, pituitary cancer and metalloproteinase
18) Confidence 0.08 Published 2009 Journal J Clin Neurosci Section Abstract Doc Link 19046883 Disease Relevance 1.08 Pain Relevance 0.18
Overall, the most beneficial growth factor was bFGF, which was most potent in increasing proliferation and GAG synthesis, and also effective in promoting collagen synthesis.
Negative_regulation (effective) of bFGF
19) Confidence 0.07 Published 2004 Journal Arch. Oral Biol. Section Abstract Doc Link 15126139 Disease Relevance 0.30 Pain Relevance 0.30
Plasma concentrations of VEGF were similar (p=0.151) at the different time points after exercise but FGF-2 levels decreased (p=0.013).
Negative_regulation (decreased) of FGF-2 in Plasma
20) Confidence 0.07 Published 2009 Journal Eur J Vasc Endovasc Surg Section Body Doc Link 19775917 Disease Relevance 0.14 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox